<DOC>
	<DOCNO>NCT02059278</DOCNO>
	<brief_summary>This Phase 3 study evaluate safety efficacy T-2345 dose one eye daily 84 day compare Xalatan dose one eye daily 84 day patient elevate eye pressure .</brief_summary>
	<brief_title>Safety Efficacy T-2345 Compared Xalatan Subjects With Primary Open Angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description>The objective Phase 3 study evaluate efficacy safety T-2345 nonpreserved ophthalmic solution ( latanoprost 0.005 % ) comparison Xalatan® ( latanoprost 0.005 % ) subject primary open angle glaucoma ( POAG ) ocular hypertension ( OH ) . This randomized , multicenter , parallel-group , observer-masked study approximately 380 evaluable subject treat 84 day . Subjects history POAG OH elevate intraocular pressure ( IOP ) adequately control ( IOP ≤ 18 mm Hg ) latanoprost 0.005 % ophthalmic solution monotherapy least 4 week . Primary efficacy ( IOP ) assess study eye visit Goldmann applanation tonometry assessment visit . Safety assess visit correct Snellen Visual Acuity , slit lamp examination/anterior chamber cell count flare adverse event ( AE ) collection . Primary Efficacy Endpoint between-group comparison mean IOP value time point Day 15 , 42 , 84 visit . Secondary Efficacy Endpoints include : - Between-group comparison mean change baseline diurnal IOP measurement postbaseline visit . - Between-group comparison mean change baseline IOP measurement time point Day 15 , Day 42 Day 84 .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 . Age 18 year old . 2 . POAG OH IOP treat adequately control ( IOP ≤ 18 mm Hg ) latanoprost 0.005 % ophthalmic solution monotherapy least 4 week prior Screening . 3 . Each eye treat latanoprost 0.005 % ophthalmic solution monotherapy must mean IOP ≤ 18 mm Hg Screening mean IOP ≤ 28 mm Hg Baseline ; measurement take visit 8 AM , 10 AM , 4 PM ( ± 30 minute ) AM measurement IOP least 2 hour apart . If one eye qualify eye glaucoma fellow eye require antiglaucoma medication , subject qualify trial . 4 . Stable visual field ( VF ) , define sign VF degradation two consecutive 302 two consecutive 242 VF examination . For subject VF defect ( eg , OH ) , single , normal VF examination perform ˂ 6 month prior screen visit allow determine eligibility . For patient abnormal VF examination , follow criterion apply : Two VF ( recent VF past VF ) examination perform least ≥ 6 month ≤ 18 month apart must compare ; The recent VF examination perform &lt; 6 month prior Screening visit ; The past VF examination perform ≥ 6 month ≤ 18 month prior recent VF test . 5 . Stable correct Snellen visual acuity ( VA ) good 20/200 study eye . Patients must see ≥ 50 % letter single line accept VA line . 6 . Central corneal thickness 480620 μm study eye . 7 . Shaffer gonioscopic grade ≥ 3 ( least 3 quadrant ) eye . 8 . Female subject must 1year postmenopausal , surgically sterilize , woman childbearing potential negative urine pregnancy test Screening . Women childbearing potential must use acceptable form contraception throughout study . Acceptable method include use least one following : intrauterine ( intrauterine device ) , hormonal ( oral , injection , patch , implant , ring ) , barrier spermicide ( condom , diaphragm ) , abstinence . 9 . All subject must provide sign write consent prior participation studyrelated procedure . In study eye : 1 . A mean deviation &lt; 20 dB VF examination . 2 . A mean IOP ˃ 28 mm Hg Baseline . 3 . Presence scotoma within 5° fixation VF examination . 4 . Aphakia . 5 . Use antiglaucoma medication addition latanoprost 0.005 % ophthalmic solution within 2 week prior Screening antiglaucoma medication ( latanoprost ) study period randomize study medication . 6 . Use topical ophthalmic steroid within 2 week prior Baseline . A short course oral steroid acceptable course complete &gt; 2 week prior Screening . Inhaled intranasal steroid acceptable . 7 . Use topical nonsteroidal antiinflammatory drug ( NSAID ) within 2 week prior Baseline . 8 . Use ophthalmic medication study period ( nonpreserved artificial tear allow ) . 9 . Ocular surgery laser treatment kind study eye within 3 month prior Baseline . 10 . History ocular allergy/inflammation and/or severe blepharitis and/or uveitis . Seasonal allergic conjunctivitis acceptable ( avoid enrollment subject may experience seasonal flareup study period ) . Mild blepharitis/blepharoconjunctivitis , typically associate prostaglandin usage , lid acceptable . 11 . History ocular trauma ocular infection within 3 month Screening . 12 . History herpes simplex keratitis . 13 . Current proliferative diabetic retinopathy agerelated macular degeneration , unless deem clinically significant Investigator . 14 . Severe dry eye ( eg , clinically relevant superficial punctate keratitis , epithelial erosion cornea , and/or use dry eye medication [ include artificial tear ] frequency exceed 8 instillation per day ) . 15 . Contact lens wear study period . Contact lens wear untreated fellow eye allow . 16 . Any secondary glaucoma OH ( eg , congenital glaucoma , closedangle glaucoma , uveitic glaucoma , pseudoexfoliation syndrome ) . 17 . Any severe glaucoma define cup ( cuptodisc ratio ≥ 0.8 ) . 18 . Any nonlaser glaucoma surgery . 19 . Any abnormality prevent accurate assessment ( eg , result unreliable applanation tonometry VF examination ) . General : 20 . Pregnancy lactation . 21 . Uncontrolled asthma ( define asthma respond maximum guidelinedirected therapy ) . 22 . Allergy benzalkonium chloride . 23 . History moderate severe renal hepatic impairment . 24 . Participation study investigational product within 30 day prior Screening time study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Primary open angle glaucoma</keyword>
	<keyword>Ocular hypertension</keyword>
</DOC>